192 related articles for article (PubMed ID: 33914911)
1. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Masarova L; Naqvi K; Jabbour E; DiNardo CD; Takahashi K; Konopleva M; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Borthakur G; Estrov Z; Khoury JD; Loghavi S; Soltysiak KA; Pierce S; Bueso-Ramos C; Patel KP; Verstovsek S; Kantarjian HM; Bose P; Garcia-Manero G
Cancer; 2021 Sep; 127(17):3113-3124. PubMed ID: 33914911
[TBL] [Abstract][Full Text] [Related]
2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
3. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
4. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
5. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
[TBL] [Abstract][Full Text] [Related]
6. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
[TBL] [Abstract][Full Text] [Related]
7. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature.
Wang L; Du F; Zhang HM; Wang HX
Braz J Med Biol Res; 2015 Jul; 48(7):583-7. PubMed ID: 26017341
[TBL] [Abstract][Full Text] [Related]
9. Atypical chronic myeloid leukemia: a rare entity with management challenges.
Dhakal P; Gundabolu K; Amador C; Rayamajhi S; Bhatt VR
Future Oncol; 2018 Jan; 14(2):177-185. PubMed ID: 29226717
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
11. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
[TBL] [Abstract][Full Text] [Related]
12. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
13. How I treat atypical chronic myeloid leukemia.
Gotlib J
Blood; 2017 Feb; 129(7):838-845. PubMed ID: 27899359
[TBL] [Abstract][Full Text] [Related]
14. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
[TBL] [Abstract][Full Text] [Related]
16. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
Muramatsu H; Makishima H; Maciejewski JP
Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
[TBL] [Abstract][Full Text] [Related]
18. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
19. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
20. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]